Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 669.00 GBp
Change Today -17.00 / -2.48%
Volume 457.8K
BTG On Other Exchanges
Symbol
Exchange
Berlin
OTC US
OTC US
As of 11:35 AM 07/3/15 All times are local (Market data is delayed by at least 15 minutes).

btg plc (BTG) Snapshot

Open
685.50 GBp
Previous Close
686.00 GBp
Day High
685.50 GBp
Day Low
669.00 GBp
52 Week High
01/9/15 - 834.50 GBp
52 Week Low
07/28/14 - 578.50 GBp
Market Cap
2.6B
Average Volume 10 Days
771.8K
EPS TTM
0.09 GBp
Shares Outstanding
382.8M
EX-Date
06/7/00
P/E TM
71.9x
Dividend
--
Dividend Yield
--
Current Stock Chart for BTG PLC (BTG)

Related News

No related news articles were found.

btg plc (BTG) Related Businessweek News

No Related Businessweek News Found

btg plc (BTG) Details

BTG plc, a specialist healthcare company, acquires, develops, and commercializes pharmaceutical products worldwide. It operates through three segments: Interventional Medicine, Specialty Pharmaceuticals, and Licensing. The Interventional Medicine segment offers oncology products, including Beads and TheraSphere for the treatment of liver tumours; pulmonology products comprising RePneu Coil system for the treatment of emphysema; and vascular products, such as EkoSonic for severe blood clots, as well as Varithena for moderate to severe varicose veins. The Specialty Pharmaceuticals segment provides acute care and antidote products, such as CroFab for crotalid snakebites; DigiFab for digoxin toxicity; and Voraxaze for high-dose methotrexate toxicity. The Licensing segment offers Abiraterone acetate for advanced prostate cancer; Alemtuzumab for multiple sclerosis; and Two-Part Hip Cup for hip replacement. BTG plc is also developing uridine triacetate that is in late-stage of clinical trials for life-threatening toxic side effects of overexposure to the chemotherapeutic 5-fluorouracil. The company also manufactures and commercializes therapeutic ultrasound devices. BTG plc was founded in 1948 and is headquartered in London, the United Kingdom.

1,121 Employees
Last Reported Date: 05/18/15
Founded in 1948

btg plc (BTG) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 1.1M GBP
Chief Financial Officer, Executive Director a...
Total Annual Compensation: 707.0K GBP
Compensation as of Fiscal Year 2015.

btg plc (BTG) Key Developments

BTG plc Announces Treatment of First Patient in Singapore with Therasphere Radioembolization Therapy

BTG plc announced the treatment of the first patient in Singapore with TheraSphere, a treatment for primary liver cancer and metastatic colorectal cancer, specifically engineered to deliver powerful doses of radiation to the tumour while minimizing exposure to normal tissue. TheraSphere is a targeted therapy that consists of millions of glass microspheres containing radioactive yttrium-90. The microspheres are about 20-30 micrometers in diameter, about a third of the width of a human hair. They are delivered directly to liver tumours through the hepatic artery using a catheter. The glass microspheres flow directly into the liver tumour through its blood vessels and become permanently lodged there. Because the procedure delivers the treatment directly to the liver tumour, the radiation destroys the tumour cells with minimal impact to the surrounding healthy liver tissue. The radioactive microspheres continue to deliver radiation to the tumour over the course of several weeks after treatment. TheraSphere can also be used as a bridge to surgical removal of diseased tissue or transplantation in these patients.

BTG plc Announces Revolens Study Results

BTG plc announced the presentation of top line data showing that REVOLENS, a randomized, controlled trial sponsored by the French Ministry of Health, met its primary endpoint. The results show that the PneumRx endobronchial coil is superior to the standard of care for improving exercise capacity in patients with severe emphysema at 6 months as measured by the 6 minute walk test (6MWT). The results were presented by Professor Gaetan Deslee of the University Hospital of Reims, France at the American Thoracic Society (ATS) International Conference in Denver, Colorado. The REVOLENS study randomized 100 patients with severe emphysema from 10 centres in France. The primary outcome measure was the rate of patients showing an improvement greater than or equal to 54 metres distance in the 6MWT at 6 months. An intention to treat analysis showed that the rate of patients meeting the primary endpoint was superior in the coil group (36%) compared to the standard of care group (18%) (P<0.05). REVOLENS (réduction de volume par voie endobronchique par spirales) was a prospective multicenter randomised controlled superiority trial comparing coil treatment with the standard of care in severe emphysema. The study was funded by the French Ministry of Health under the soutien aux techniques innovantes couteuses (STIC) program, which provides government funding for innovative medical technologies that have been validated by prior clinical studies, with a view toward establishing reimbursement for new devices. Developed by PneumRx, a BTG group company, the endobronchial coil is a minimally invasive device intended to improve exercise capacity, lung function, and quality of life for severe emphysema patients. The device has a CE Mark and has been used in Europe for the treatment of emphysema since 2010. Coil treatment is being studied under an Investigational Device Exemption (IDE) in the United States and is not yet approved for commercial use by the FDA. The RENEW Clinical Study, a Phase III pivotal trial of 315 patients completed enrolment in October of 2014 and a US regulatory submission is planned for 2016.

BTG plc Announces Consolidated Final Earnings Results for the Year Ended March 31, 2015; Provides Guidance for the Fiscal 2016

BTG plc announced consolidated final earnings results for the year ended March 31, 2015. For the year, the company reported revenue was £367.8 million against £290.5 million a year ago. Operating profit was £34.9 million against £27.3 million a year ago. Profit before tax was £26.7 million against £33.3 million a year ago. Profit was £33.6 million against £24.3 million a year ago. Diluted earnings per share were 9.0 pence against 6.7 pence a year ago. Net cash inflow from operating activities was £47.5 million against £48.5 million a year ago. Purchases of intangible assets were £1.4 million against £0.9 million a year ago. Purchases of property, plant and equipment was £9.8 million against £11.6 million a year ago. Underlying earnings was £57.8 million against £51.5 million a year ago. Underlying diluted earnings per share were 15.4 pence against 14.3 pence a year ago. The company anticipates further growth in the current financial year 2016, with revenue expected to be in the range £410 million to £440 million (at an exchange rate of £1:$1.61). As company utilizes losses, the company expected to have a low effective tax rate in the short term. The company predicted effective tax rate in the mid- to high-teens for next year and this will increase in the longer term to an effective tax rates of around 26%.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BTG:LN 669.00 GBp -17.00

BTG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Merit Medical Systems Inc $21.30 USD -0.11
Pfizer Ltd/India 1,980 INR -26.10
RPX Corp $16.75 USD -0.27
Sirtex Medical Ltd A$30.50 AUD -0.10
Medicines Co/The $31.28 USD +2.94
View Industry Companies
 

Industry Analysis

BTG

Industry Average

Valuation BTG Industry Range
Price/Earnings 80.3x
Price/Sales 7.4x
Price/Book 3.6x
Price/Cash Flow 44.6x
TEV/Sales 7.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BTG PLC, please visit www.btgplc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.